These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24501285)

  • 41. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Building avatar armies with fish and flies.
    Neff EP
    Lab Anim (NY); 2020 Apr; 49(4):101-104. PubMed ID: 32210417
    [No Abstract]   [Full Text] [Related]  

  • 43. What's Next for Patient-Derived Xenograft Modeling?
    Gritters J
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 29982758
    [No Abstract]   [Full Text] [Related]  

  • 44. Soviet scientists in chinese institutes: A historical study of cooperation between the two academies of sciences in 1950s.
    Zhang J; Yu FT
    Endeavour; 2018 Mar; 42(1):17-26. PubMed ID: 29548563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
    Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
    Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urban conservation and environmental protection in China: a major effort by the Chinese Academy of Sciences.
    Ehrenfeld D; Yu S; Zhu Y
    Conserv Biol; 2009 Jun; 23(3):546-7. PubMed ID: 22748092
    [No Abstract]   [Full Text] [Related]  

  • 47. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer.
    Decaudin D
    Anticancer Drugs; 2011 Oct; 22(9):827-41. PubMed ID: 21623183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Application of zebrafish model organism in the research of Chinese materia medica].
    Chen L; Liu Y; Liang SW
    Yao Xue Xue Bao; 2012 Apr; 47(4):434-9. PubMed ID: 22799023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing therapy response in patient-derived xenografts.
    Ortmann J; Rampášek L; Tai E; Mer AS; Shi R; Stewart EL; Mascaux C; Fares A; Pham NA; Beri G; Eeles C; Tkachuk D; Ho C; Sakashita S; Weiss J; Jiang X; Liu G; Cescon DW; O'Brien CA; Guo S; Tsao MS; Haibe-Kains B; Goldenberg A
    Sci Transl Med; 2021 Nov; 13(620):eabf4969. PubMed ID: 34788078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SIRPAssing other xenograft murine models?
    Rau RE
    Blood; 2020 May; 135(19):1612-1614. PubMed ID: 32379878
    [No Abstract]   [Full Text] [Related]  

  • 51. [Position of the Presidium of the Hungarian Academy of Sciences on the human use of the preparation Celladam].
    Orv Hetil; 1987 Jun; 128(26):1339-43. PubMed ID: 3614895
    [No Abstract]   [Full Text] [Related]  

  • 52. Genetically engineered models have advantages over xenografts for preclinical studies.
    Becher OJ; Holland EC
    Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
    Rubio-Viqueira B; Hidalgo M
    Clin Pharmacol Ther; 2009 Feb; 85(2):217-21. PubMed ID: 19005462
    [No Abstract]   [Full Text] [Related]  

  • 54. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk J; Rolff J; Becker M; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Materials science at the Institute of Chemistry, Chinese Academy of Sciences.
    Zhang DQ
    Adv Mater; 2014 Oct; 26(40):6809. PubMed ID: 25339275
    [No Abstract]   [Full Text] [Related]  

  • 56. In vivo target validation by inducible RNAi in human xenograft mouse models.
    Mazzoletti M; Texidó G
    Methods Mol Biol; 2013; 986():325-37. PubMed ID: 23436421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Priorities and funding. "Knowledge innovation" and the Chinese Academy of Sciences.
    Suttmeier RP; Cao C; Simon DF
    Science; 2006 Apr; 312(5770):58-9. PubMed ID: 16601178
    [No Abstract]   [Full Text] [Related]  

  • 58. Modeling of human tumor xenografts and dose rationale in oncology.
    Simeoni M; De Nicolao G; Magni P; Rocchetti M; Poggesi I
    Drug Discov Today Technol; 2013 Sep; 10(3):e365-72. PubMed ID: 24050133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The returning tide: how China, the world's most populous country, is building a competitive research base.
    Wells WA
    J Exp Med; 2007 Feb; 204(2):210-35. PubMed ID: 17296791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.